{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T08:31:11Z","timestamp":1777883471023,"version":"3.51.4"},"reference-count":59,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Medical Education Collaborative Innovation Fund, Jiangsu University","award":["JDY2023016"],"award-info":[{"award-number":["JDY2023016"]}]},{"name":"the \u201cNational Tutorial System\u201d Training Program for Key Young Health Professionals in Suzhou","award":["Qngg2023048"],"award-info":[{"award-number":["Qngg2023048"]}]},{"name":"Medical Research Project, Jiangsu Provincial Health Commission","award":["Z2023039"],"award-info":[{"award-number":["Z2023039"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Sage Open Chronic Disease"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The management of idiopathic membranous nephropathy (IMN) continues to be a significant challenge to date. A limited number of observational studies have compared Obinutuzumab\u2019s (OBZ) therapeutic potential, with OBZ appearing to be more effective than rituximab (RTX) in achieving clinical remission.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>This study was designed to evaluate the effectiveness and safety profile of OBZ for IMN treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>Clinical studies regarding the application of OBZ for IMN were included, and the effector sizes were pooled by meta-analysis. Sensitivity analysis and subgroup analysis were adopted to evaluate the robustness and reliability of the findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources and methods:<\/jats:title>\n                    <jats:p>Several electronic databases were systematically searched for relevant studies. Effectors, including the rates of total remission (TR) and complete remission (CR), reported in these studies were extracted and pooled as non-comparative binary variables. The rates of immunologic remission, B-cell depletion, and adverse events (AEs) were recorded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Among the studies retrieved in the initial search, 9 eligible studies with 344 participants were included in this meta-analysis. OBZ therapy increased the TR rates at 6\u2009months (0.78 (0.71, 0.85)) and 12\u2009months (0.88 (0.82, 0.93)) and improved the CR rates at 6\u2009months (0.13 (0.03, 0.23)) and 12\u2009months (0.27 (0.16, 0.39)) compared to RTX. No evident heterogeneity or publication bias was observed. The results persisted in the subgroup analysis in terms of OBZ, as the initial treatment for membranous nephropathy (MN), for refractory MN, or for RTX-refractory MN. Interestingly, OBZ treatment was linked to a greater probability of achieving TR than RTX treatment (At 6\u2009months, odds ratio was 4.07 (1.94, 8.53)) and (At 12\u2009months, odds ratio was 10.79 (3.38, 34.39)). OBZ therapy consistently led to a relatively high rate of immunological remission and effective B-cell clearance and did not increase the incidence of AEs or severe AEs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>OBZ therapy is associated with improved clinical remission and might be an attractive option for patients with IMN, especially those with refractory or RTX-refractory IMN. High-quality clinical studies are, however, warranted to validate these results further.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration:<\/jats:title>\n                    <jats:p>This study was registered as a meta-analysis in PROSPERO (Number: CRD42025635162).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/27558428261421704","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T05:45:41Z","timestamp":1774676741000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["A meta-analysis on the efficacy and safety of obinuzumab for membranous nephropathy"],"prefix":"10.1177","volume":"17","author":[{"given":"Li-Xia","family":"Yu","sequence":"first","affiliation":[{"name":"Department of Nephrology, Affiliated Kunshan Hospital of Jiangsu University, Jiangsu, China"},{"name":"Gusu School, The First People\u2019s Hospital of Kunshan, Nanjing Medical University, Kunshan, Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuan-Li","family":"Qian","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Affiliated Kunshan Hospital of Jiangsu University, Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing-Rong","family":"Qian","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Affiliated Kunshan Hospital of Jiangsu University, Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Qi-Zhang","sequence":"additional","affiliation":[{"name":"Gusu School, The First People\u2019s Hospital of Kunshan, Nanjing Medical University, Kunshan, Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu-Li","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Affiliated Kunshan Hospital of Jiangsu University, Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1224-3750","authenticated-orcid":false,"given":"Qi-Feng","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Affiliated Kunshan Hospital of Jiangsu University, Jiangsu, China"},{"name":"Gusu School, The First People\u2019s Hospital of Kunshan, Nanjing Medical University, Kunshan, Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2026,3,27]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.3390\/biom11040513"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.611317"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2007020166"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-022-00564-1"},{"key":"e_1_3_2_6_2","article-title":"The prognostic value of phospholipase A2 receptor autoantibodies on spontaneous remission for patients with idiopathic membranous nephropathy: a meta-analysis","volume":"97","author":"Wu W","year":"2018","unstructured":"Wu W, Shang J, Tao C, et al. The prognostic value of phospholipase A2 receptor autoantibodies on spontaneous remission for patients with idiopathic membranous nephropathy: a meta-analysis. Medicine (Baltimore) 2018; 97: e11018.","journal-title":"Medicine (Baltimore)"},{"key":"e_1_3_2_7_2","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group","year":"2021","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int 2021; 100: S1\u2013S276.","journal-title":"Kidney Int"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-022-03372-5"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2019.03.002"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.917532"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1814427"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nephro.2021.10.002"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-017-0612-x"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfad225"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15232"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-225979"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfad041"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nefroe.2024.03.004"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-022-02761-3"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2020.02.444"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2024.05.004"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfae230"},{"key":"e_1_3_2_23_2","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372: n71.","journal-title":"BMJ"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.108635"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1445-2197.2003.02748.x"},{"key":"e_1_3_2_26_2","first-page":"889","article-title":"Implement Meta-Analysis with Non-Comparative Binary Data in RevMan Soft ware","volume":"14","author":"Chen YH","year":"2014","unstructured":"Chen YH, Du L, Geng XY, et al. Implement Meta-Analysis with Non-Comparative Binary Data in RevMan Soft ware. Chin J Evid Based Med 2014; 14: 889\u2013896.","journal-title":"Chin J Evid Based Med"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.5114\/aoms.2020.99899"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000000562"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2024.12.012"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-025-04407-3"},{"key":"e_1_3_2_31_2","first-page":"1","article-title":"Obinutuzumab in treatment of high risk or refractory phospholipase A2 receptor associated membranous nephropathy [in Chinese]","volume":"34","author":"Chen DQ","year":"2025","unstructured":"Chen DQ, Tu YM, Li H, et al. Obinutuzumab in treatment of high risk or refractory phospholipase A2 receptor associated membranous nephropathy [in Chinese]. J Nephrol Dialy Transplant 2025; 34: 1\u20137.","journal-title":"J Nephrol Dialy Transplant"},{"key":"e_1_3_2_32_2","first-page":"572","article-title":"Treatment of phospholipase A2 receptor associated membranous nephropathy with obinutuzumab: a report of ten cases with a literature review [in Chinese]","volume":"24","author":"Yan M","year":"2024","unstructured":"Yan M, Liang W. Treatment of phospholipase A2 receptor associated membranous nephropathy with obinutuzumab: a report of ten cases with a literature review [in Chinese]. J Clin Nephrol 2024; 24: 572\u2013578.","journal-title":"J Clin Nephrol"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2024.100853"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.0000000000000555"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/nep.14331"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfae299"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfaf039"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2022.12.011"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2020.11.028"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.822508"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01855-y"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.805697"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex067"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab916"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18192"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220920"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224999"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfae061"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-024-06570-8"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2020.06.030"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00163"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2015.07.003"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-016-0451-1"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0647"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25560"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000000107"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1097\/TXD.0000000000001436"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.15514"},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614598"},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000919"}],"container-title":["Sage Open Chronic Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/27558428261421704","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/27558428261421704","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/27558428261421704","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T01:46:56Z","timestamp":1777600016000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/27558428261421704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":59,"alternative-id":["10.1177\/27558428261421704"],"URL":"https:\/\/doi.org\/10.1177\/27558428261421704","relation":{},"ISSN":["2755-8428","2978-1558"],"issn-type":[{"value":"2755-8428","type":"print"},{"value":"2978-1558","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"article-number":"27558428261421704"}}